SEC begins inquiry into Aveo

Investigators from the Securities and Exchange Commission have subpoenaed documents from Aveo Pharmaceuticals Inc. relating to an experimental drug for kidney cancer that was rejected by the Food and Drug Administration in June, the Cambridge company said Thursday.

In a regulatory filing, Aveo said it “intends to fully cooperate with the SEC regarding this non-public, fact-finding inquiry.”


The SEC has informed the company “that this inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity, or security,” according to the filing.

Aveo officials do not intend to comment publicly beyond the filing, a company spokesman said Thursday night.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of